Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, discusses the importance of testing for homologous recombination repair deficiency (HRD) at diagnosis in patients with ovarian cancer, for example enabling identification of sensitivity to PARP inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.